Good Morning, Market Enthusiast!
 

We’ve got some electrifying news to share today about a company that’s not just making waves but is on the verge of transforming the biotech landscape. TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) is gaining serious momentum, with premarket energy already showing a thrilling more than 10% jump! (2)
 

This company is looking more exciting by the minute, and with their latest clinical results, they’re poised to take the industry by storm.
 

Why This Latest News is a Game-Changer:
 

🔬 Breakthrough Clinical Results

TNF Pharmaceuticals has just announced significant progress with their lead drug, MYMD-1®. In their latest mid-stage trials, MYMD-1® achieved its primary endpoints, significantly reducing chronic inflammation with no adverse events. This is a huge win, especially as the company gears up for further studies targeting age-related muscle loss (sarcopenia) and chronic inflammation. (1)(4)
 

💥 Expanding Into New Markets

What makes this news even more exciting is that TNF Pharmaceuticals is ready to take MYMD-1® beyond just sarcopenia. With FDA clearance already in hand, they’re preparing to launch Phase 2 trials for rheumatoid arthritis and Hashimoto’s thyroiditis. These conditions represent enormous market potentials, and success here could position TNF Pharmaceuticals as a leader in treating chronic inflammatory diseases. (1)(4)
 

(1)

😎 Fully Funded and Ready to Roll

One of the most impressive aspects of this news is that TNF Pharmaceuticals has secured full funding for their upcoming clinical trials. This financial backing not only demonstrates strong confidence in the company’s potential but also ensures that they have the resources needed to keep advancing without interruption. (1)(4)
 

🏆 First-in-Class Potential

MYMD-1® isn’t just another drug in development – it has the potential to become the first oral TNF-alpha inhibitor on the market. If successful, this would mark a major shift in how age-related diseases and chronic inflammation are treated, offering a simpler, more accessible option for millions of patients. (1)(4)
 

What’s Next for TNF Pharmaceuticals?

With this latest success under their belt and more trials on the horizon, TNF Pharmaceuticals is positioned to make significant strides in the biotech space. 

Their commitment to advancing treatments for some of the most challenging conditions means this is one company you’ll want to watch NOW!
 

Stay tuned – TNF Pharmaceuticals (Nasdaq: TNFA) is just getting started, and the best is yet to come!

‼️ ATTENTION ‼️ 

We’re moving to a new WhatsApp Community! Stay in the loop with Market Tips by joining us at the link below:

To your success,

Max Masters

Co-founder, Market Tips Newsletter

Sources:
1. https://finance.yahoo.com/news/tnf-pharmaceuticals-prepares-advance-lead-130000585.html
2. https://finance.yahoo.com/quote/TNFA/
3. https://finance.yahoo.com/quote/TNFA/history/
4. https://ir.tnfpharma.com/

Data is provided from third-party sources and Market Tips is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile I bring to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized fin.ancial advice, are not finan.cial advisors, and our opinions are not suitable for all in.vest.ors. Please review our full disc.laim.er here. 

Pursuant to an agreement between Momentum Media LLC and Sica Media LLC, Momentum Media LLC has been hired for a period beginning on 08/21/2024 and ending on 08/22/2024 to publicly disseminate information about (TNFA:US) via digital communications. To date we have been paid eight thousand dollars USD. We own zero shares of (TNFA:US).